US5015751044
US5015751044
Kymera Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 39.211.000 | 47.072.000 | 16.7% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 384.755.000 | 303.782.000 | 26.7% | |
| Operating Income | -345.544.000 | -256.710.000 | 34.6% |
| Pretax Income | -311.351.000 | -223.858.000 | 39.1% |
| Net Income Common Stockholders | -311.351.000 | -223.858.000 | 39.1% |
| -- | -- | -- | |
| -- | -- | -- |